Procter & Gamble Hygiene and Health Care Limited
CIN: L24239MH1964PLC012971
Registered Office:
P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
Tel: (91-22) 6958 6000
Fax: (91-22) 6958 7337
Website: in.pg.com

November 12, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Ref:- Scrip Code:- 500459

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Scrip Code:- PGHH

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter and half year ended September 30, 2026

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today i.e. November 12, 2026, (commenced at 01:14 P.M. and ended at 01:27 P.M.), the Unaudited Financial Results along with the Statement of Assets and Liabilities and Statement of Cash flows for the quarter and half year ended September 30, 2026 were approved.

We are enclosing herewith the following:

a. Unaudited Financial Results along with the Statement of Assets and Liabilities and Statement of Cash flows for the quarter and half year ended September 30, 2026;
b. Limited Review Report, in respect of the Unaudited Financial Results for the quarter and half year ended September 30, 2026, as furnished by the Statutory Auditors of the Company;

Kindly take the same on record.

Thanking you,
Yours faithfully,

For **Procter & Gamble Hygiene and Health Care Limited**

Flavia Peter Machado
Digitally signed by Flavia Peter Machado
Date: 2026.11.12 13:29:54 +05'30'

Flavia Machado
Company Secretary & Compliance Officer
ACS: 38986

Procter & Gamble Hygiene
and Health Care Limited
CIN : L24239MH1964PLC012971
Registered Office: P&G Plaza
Cardinal Gracias Road, Chakala
Andheri (E), Mumbai 400 099
Tel: (91 – 22) 6958 6000
Fax: (91 – 22) 6958 7337
Website: in.pg.com

(₹ in Lakhs)

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30th SEPTEMBER 2026

	Particulars	(1) Three Months Ended 30th September 2026	(2) Preceding Three Months Ended 30th June 2026	(3) Corresponding Three Months Ended 30th September 2025	(4) Six Months Ended 30th September 2026	(5) Corresponding Six Months Ended 30th September 2025	(6) Previous Year Ended 31st March 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Income**						
	Sale of products	1 14 306	88 992	1 14 885	2 03 298	2 08 401	4 28 159
	Other operating revenues	202	154	132	356	319	883
2	**Revenue from operations**	**1 14 508**	**89 146**	**1 15 017**	**2 03 654**	**2 08 720**	**4 29 042**
3	Other income	1 701	943	990	2 644	1 759	4 247
	Total income (2+3)	**1 16 209**	**90 089**	**1 16 007**	**2 06 298**	**2 10 479**	**4 33 289**
4	**Expenses**						
a)	Cost of raw and packing materials consumed	23 787	20 024	19 749	43 811	36 189	73 811
b)	Purchases of stock-in-trade (Traded goods)	23 752	21 323	21 164	45 075	41 412	82 396
c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(531)	(3 322)	3 607	(3 853)	1 036	308
d)	Employee benefits expense	5 486	5 436	4 859	10 922	9 694	21 514
e)	Finance costs	367	27	360	394	367	945
f)	Depreciation and amortization expense	1 144	959	928	2 103	1 837	3 743
g)	Advertising & sales promotion expenses	16 662	8 332	17 597	24 994	24 470	52 272
h)	Other expenses	19 340	20 347	19 565	39 687	40 826	81 637
	Total expenses	**90 007**	**73 126**	**87 829**	**1 63 133**	**1 55 831**	**3 16 626**
5	**Profit before tax (2+3-4)**	**26 202**	**16 963**	**28 178**	**43 165**	**54 648**	**1 16 663**
6	**Income tax expense**						
a)	Current tax	6 736	4 389	7 419	11 125	14 081	29 995
b)	Deferred tax	(118)	(53)	(227)	(171)	(147)	632
c)	Prior year tax adjustments	—	—	—	—	522	386
		6 618	**4 336**	**7 192**	**10 954**	**14 456**	**31 013**
7	**Profit for the period (5-6)**	**19 584**	**12 627**	**20 986**	**32 211**	**40 192**	**85 650**
8	**Other comprehensive income / (loss)**						
	Items that will not be reclassified to profit or loss						
	Remeasurement of the defined benefit plans	(18)	143	557	125	321	573
	Income tax effect on above	5	(36)	(140)	(31)	(81)	(144)
	Total other comprehensive income / (loss) for the period	**(13)**	**107**	**417**	**94**	**240**	**429**
9	**Total comprehensive income for the period (7+8)**	**19 571**	**12 734**	**21 403**	**32 305**	**40 432**	**86 079**
10	Paid-up equity share capital (Face Value ₹ 10 per equity share)	3 246	3 246	3 246	3 246	3 246	3 246
11	Other Equity						72 101
12	**Earnings per Share (Face value of ₹ 10 per equity share) (not annualised) :**						
a)	Basic (in ₹)	60.33	38.90	64.65	99.23	123.82	263.86
b)	Diluted (in ₹)	60.33	38.90	64.65	99.23	123.82	263.86

See accompanying notes to the financial results

KALYANIWALLA & MISTRY LLP MUMBAI

Procter & Gamble Hygiene And Health Care Ltd. Mumbai

Notes:

1 **Statement of Assets and Liabilities**

(₹ in Lakhs)

Particulars	As at 30th September 2026 (Unaudited)	As at 31st March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	16 282	16 307
Capital work-in-progress	2 797	2 127
Financial assets		
(i) Loans	4 367	4 127
(ii) Other financial assets	456	456
Deferred tax assets (Net)	7 642	7 502
Non-current tax assets (Net)	22 837	22 815
Other non-current assets	14 885	12 623
Total non-current assets	**69 266**	**65 957**
Current assets		
Inventories	30 592	21 793
Financial assets		
(i) Trade receivables	27 374	24 277
(ii) Cash and cash equivalents	71 580	55 702
(iii) Bank balances other than (ii) above	1 042	1 092
(iv) Loans	513	511
(v) Other financial assets	5 063	5 719
Other current assets	6 727	5 303
	1 42 891	1 14 397
Non current assets held for sale	781	—
Total current assets	**1 43 672**	**1 14 397**
Total Assets	**2 12 938**	**1 80 354**
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	3 246	3 246
Other equity	85 163	72 101
Total Equity	**88 409**	**75 347**
LIABILITIES		
Non-current liabilities		
Financial liabilities		
(i) Lease liabilities	17	1
Provisions	11 752	11 483
Total non-current liabilities	**11 769**	**11 484**
Current liabilities		
Financial liabilities		
(i) Lease liabilities	16	86
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises	887	1 675
Total outstanding dues of creditors other than micro enterprises and small enterprises	99 165	82 791
(iii) Other financial liabilities	1 610	2 346
Other current liabilities	8 004	5 478
Provisions	1 426	1 147
Current tax liabilities (net)	1 652	—
Total current liabilities	**1 12 760**	**93 523**
Total Liabilities	**1 24 529**	**1 05 007**
Total Equity and Liabilities	**2 12 938**	**1 80 354**

KALYANIWALLA & MISTRY LLP MUMBAI

Procter & Gamble Hygiene And Health Care Ltd. Mumbai

2 Statement of Cash Flows

(₹ in Lakhs)

Particulars	Six Months Ended 30th September 2026 (Unaudited)	Six Months Ended 30th September 2025 (Unaudited)
A. Cash Flows from Operating Activities		
Profit before tax	**43 165**	**54 648**
Adjustments for:		
Depreciation and amortization expense	2 103	1 837
(Gain) / Loss on disposal of property, plant and equipment	55	182
Finance costs	383	356
Allowance for doubtful receivables (Net of recovery)	(96)	132
Interest income	(1 642)	(1 662)
Net foreign exchange (Gain) / loss	(226)	206
Inventory written off (net of insurance claims recovered)	12	1 392
Liabilities / Provisions written back	(781)	—
Expense recognised in respect of equity settled share based payments	291	274
Operating profit before working capital changes	**43 264**	**57 365**
Working capital adjustments		
(Increase) in trade and other receivables	(3 034)	(5 643)
Decrease / (Increase) in financial assets	555	(3 288)
(Increase) in inventories	(8 811)	(876)
(Increase) / Decrease in other assets	(3 686)	436
Increase in trade and other payables	18 288	15 723
Increase / (Decrease) in provisions	306	(209)
Cash generated from operations	**46 882**	**63 508**
Income taxes paid (net of refund)	(9 495)	(11 668)
Net cash generated from operating activities	**37 387**	**51 840**
B. Cash Flows from Investing Activities		
Interest received	1 501	1 545
Payment to acquire property, plant and equipment and capital work-in-progress	(3 540)	(2 914)
Proceeds from sale of property, plant and equipment	56	1 826
Net bank deposits (placed)	—	1
Changes in earmarked balances	(50)	400
Net cash (used in) / generated from investing activities	**(2 033)**	**858**
C. Cash Flows from Financing Activities		
Dividend paid	(19 476)	(21 099)
Principal payment of lease liabilities	—	(26)
Interest paid on lease liabilities	(3)	—
Interest paid on income tax	(2)	—
Net cash (used in) financing activities	**(19 481)**	**(21 125)**
Net increase in cash and cash equivalents	**15 873**	**31 573**
Cash and cash equivalents at the beginning of the period	55 702	46 637
Exchange difference on translation of foreign currency cash and cash equivalents	5	—
Cash and cash equivalents at the end of the period	**71 580**	**78 210**

3 The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 12th November, 2026 and have been subjected to a limited review by the Statutory Auditors of the Company. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

4 The Company's operating segments under Ind AS 108 – Operating Segments are as follows:
- Health Care Products – Comprising of Ointment and Creams, Cough Drops and Tablets.
- Hygiene Products - Comprising of Feminine Hygiene products and other skin care hygiene.

These individual operating segments have been aggregated into a single primary reportable segment i.e. manufacturing, trading and marketing of Health and Hygiene Products in accordance with Ind AS 108-Operating Segments. Accordingly, no separate segment information has been provided.

5 The Statement of Assets and Liabilities as at September 30, 2026, is attached therewith as Note 1.

6 The Statement of Cash Flows has been prepared under the indirect method as set out in Ind AS -7 on the "Statement of Cash Flows" and is attached herewith as Note 2.

7 The Unaudited Financial Results are prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS-34), as prescribed under Section 133 of the Companies Act, 2013, read with relevant Rules issued thereunder and other accounting principles generally accepted in India.

8 The Company does not have a subsidiary, associate or a joint venture as at September 30, 2026.

KALYANIWALLA & MISTRY LLP MUMBAI

For and on behalf of the Board of Directors of
Procter & Gamble Hygiene and Health Care Limited

Srividya Srinivasan
Whole-time director and CFO
DIN: 10823130

Procter & Gamble Hygiene And Health Care Ltd. Mumbai

Place: Mumbai
Date: November 12, 2026

REVIEW REPORT
TO THE BOARD OF DIRECTORS
PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of ***PROCTER & GAMBLE HYGIENE AND HEALTH CARE LIMITED*** ("the Company") for the quarter and six months ended September 30,2026, together with the Statement of Unaudited Assets and Liabilities, Statement of Unaudited Cash Flows and the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification. This Statement, which is the responsibility of the Company's Management and has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 12, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Reg. No.: 104607W / W100166

Darayus Z. Fraser
PARTNER
M. No. 042454
UDIN: 26042454PIFJCD2296
Mumbai: November 12, 2026.